Later, BEN was found to have activity against chronic lymphocytic leukemia (CLL), Hodgkin’s and non-Hodgkin’s lymphomas (NHL) [2,6–8]. Here, GTF2IRD1 is linked to B-cell chronic lymphocytic leukemia.